FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases
2190PDF: 634SUPPLEMENTARY MATERIAL: 216 -
CO:09:6 | Risk of disease flare during pregnancy and postpartum in inflammatory arthritis: association with therapy discontinuation in the prospective P-RHEUM.it study Dina Zucchi1, Chiara Tani1, Francesca Crisafulli2, Alessia Gatti2, Maria Gerosa3, Cecilia Chighizola3, Melissa Padovan4, Salvatore D'Angelo5, Florenzo Iannone6, Maria Sole Chimenti7, Claudia Lomater8, Francesca Serale9, Veronique Ramoni10, Oscar Epis11, Bernd Raffeiner12, Ariela Hoxha13, Andrea Doria14, Leonardo Santo15, Valentina Canti16, Francesca Bellisai17, Giovanna Cuomo18, on behalf of the P-Rheumit Investigators19, Greta Carrara20, Cristina Di Nicola20, Davide Rozza20, Carlo Alberto Scirè20, Maria Chiara Gerardi11, Angela Tincani2, Laura Andreoli2, Marta Mosca1. | 1Rheumatology Unit, University of Pisa and Azienda Ospedaliero Universitaria Pisana; 2Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia; 3Clinical Rheumatology Division, ASST Gaetano Pini-CTO and University of Milano; 4Rheumatology Unit, Azienda Ospedaliero-Universitaria S. Anna and University of Ferrara; 5Rheumatology Department of Lucania - San Carlo Hospital, Potenza; 6Rheumatology Unit, DiMePRE-J, University of Bari; 7Department of Systems Medicine, Rheumatology, Allergology and Clinical Immunology, University of Rome-Tor Vergata, Roma; 8Torino Academic Rheumatology Center, A.O. Mauriziano di Torino, University of Torino; 9Rheumatology Unit, ASL CN1 Cuneo; 10Internal Medicine Department, ASST Lodi - Ospedale Maggiore di Lodi; 11Division of Rheumatology, Multispecialist Medical Department, Grande Ospedale Metropolitano Niguarda, Milano; 12Department of Rheumatology, Central Hospital of Bolzano SABES-ASDAA, Bolzano; 13General Medicine and Thrombosis and Hemorrhagic Unit, Department of Medicine, University of Padova; 14Rheumatology Unit, Department of Medicine, University of Padova; 15Rheumatology Unit, Mons. Dimiccoli Hospital, Barletta; 16Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milano; 17Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena; 18Precision Medicine Department, University of Campania L. Vanvitelli, Napoli; 19The Italian Society for Rheumatology; 20Epidemiology Research Unit of the Italian Society for Rheumatology, Milano, Italy
22 -
Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies
1770PDF: 81SUPPLEMENTARY MATERIAL: 310 -
S13:5 | Association between vasoactive-vasodilating therapy and reduced detection of pulmonary arterial hypertension in systemic sclerosis: evidence from a European Scleroderma Trials and Research study Nicola Farina1, Silvia Bellando-Randone1, Sebastien Sanges2, Hilde Jenssen Bjørkekjær3, Lorenzo Tofani4, Marie-Elise Truchetet5, Vanessa Smith6, Andra Balanescu7, Christina Bergmann8, Yannick Allanore9, Philipp Klemm10, Simona Truglia11, Luca Idolazzi12, Christopher Denton13, Roberta Foti14, Anna Wojteczek15, Emmanuel Chatelus16, Madelon Vonk17, Serena Guiducci1, David Launay2, Eric Hachulla2, Jeska De Vries-Bouwstra18, Anna-Maria Hoffmann-Vold19, Oliver Distler20, Marco Matucci-Cerinic1, Cosimo Bruni1. | 1Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Az, Firenze, Italy; 2Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoi, Lille, France; 3Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Norway; 4Department of Statistics, Informatics and Applications, University of Florence, Firenze, Italy; 5Rheumatology department, CHU de Bordeaux, Bordeaux, France; 6University of Ghent, Department of Rheumatology, Gent, Belgium; 7Department of Rheumatology, St. Maria Hospital, Carol Davila, University of Medicine and Pharmacy Bucharest Romania; 8Department Internal Medicine 3, University Hospital Erlangen, Erlangen, Germany; 9Rheumatology Department, Université Paris Cité, Cochin Hospital, Paris, France; 10Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff Bad Nauheim Germany; 11Reumatologia, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma, Italy; 12Section of Rheumatology, Department of Medicine, University of Verona, Verona, Italy; 13Centre for Rheumatology, Royal Free London and University College London Medical School, London, United Kingdom; 14Division of Rheumatology, A.O.U. Policlinico-San Marco, Catania, Italy; 15Department of Rheumatology, Clinical Immunology, Geriatrics and Internal Medicine, Medical University of Gdansk, Univers Gdansk Poland; 16Department of Rheumatology, University Hospital Strasbourg Strasbourg France; 17Department of rheumatology, Radboud University Nijmegen Medical Center Nijmegen The Netherlands; 18Department of Rheumatology, Leiden University Medical Center Leiden The Netherlands; 19Department of Rheumatology, Oslo University Hospital, Oslo, Norway; 20Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
16 -
PO:35:219 | Real-world effectiveness of mepolizumab on gastrointestinal involvement in eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a multicentre retrospective study Alessia Gatti1, Francesca Regola1, Giulia Fontana1, Mario Addrea Piga2, Gianluca Moroncini2, Palma Carlucci3, Angelo Vacca3, Paolo Delvino4, Enrico Heffler5, Emanuele Nappi5, Jakub Moll6, Laura Losappio6, Jan Schroeder6, Federica Davanzo7, Roberto Padoan7, Edoardo Conticini8, Paolo Cameli8, Greta Pacini9, Alvise Berti9, Lorenzo Vrola10, Paola Tomietto10, Luca Quartuccio11, Jan Willem Cohen Tervaert12, Sabrina Arnold13, Peter Lamprecht13, Florence Roufosse14, Ilaria Cavazzana1, Franco Franceschini1, Giacomo Emmi15, Paola Toniati1. | 1Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili of Brescia and University of Brescia, Italy, Brescia, Italy; 2Università Politecnica delle Marche and Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, Ancona, Italy; 3Section of Internal Medicine 'Guido Baccelli', DiMePRe-J, University of Bari 'Aldo Moro', Bari, Italy, Bari, Italy; 4Rheumatology Unit, IRCCS San Gerardo dei Tintori, Monza, Italy Monza Italy; 5Department of Biomedical Sciences, Humanitas University and Personalized Medicine, Asthma and Allergy IRCCS Humanitas, Milano, Italy; 6Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Italy, Milano, Italy; 7Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy; 8University of Siena, Siena, Italy, Siena, Italy; 9Santa Chiara Hospital and University of Trento, Unit of Rheumatology, Trento, Italy Trento Italy; 10UCO Medicina Clinica, ASUGI, Cattinara Teaching Hospital, Trieste, Italy, Trieste, Italy; 11Division of Rheumatology, Department of Medicine DMED, University of Udine, Udine, Italy, Udine, Italy; 12University of Alberta, Edmonton, Alberta, Canada and Maastricht University, Maastricht, The Netherlands Maastricht The Netherlands; 13Department of Rheumatology and Clinical Immunology, University of Lübeck, Lübeck, Germany Lubeck Germany; 14Department of Internal Medicine, Hôpital Universitaire de Bruxelles - Erasme, Université Libre de Bruxelles, Belgium Brussels Belgium; 15Clinical Medicine and Clinical Immunology and Rheumatology Unit Cattinara University Hospital and University of Trieste, Trieste, Italy.
17 -
PO:31:172 | Age and timing of onset of Raynaud's phenomenon and first non-Raynaud sign/symptom as prognostic factors in systemic sclerosis: a retrospective analysis from the systemic sclerosis progression investigation registry of the Italian Society for Rheumatology Silvia Peretti1, Cosimo Bruni2, Silvia Laura Bosello3, Fabio Cacciapaglia4-5, Corrado Campochiaro6-7, Veronica Codullo8, Lorenzo Dagna6-7, Rossella De Angelis9, Giacomo De Luca6-7, Dilia Giuggioli10, Serena Guiducci1, Florenzo Iannone4, Francesca Ingegnoli11, Valeria Riccieri12, Marco Matucci Cerinic6-7, Clodoveo Ferri10-13, Silvia Bellando Randone1. | 1Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, AO, Firenze, Italy; 2Division of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 3Rheumatology Division, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli- IRCCS, Roma, Italy; 4Rheumatology Unit, Department of Precision and Regenerative Medicine-Ionian Area, University of Bari Aldo Moro, Bari, Italy; 5Reumatology Service, Internal Medicine Unit F.Miulli General Hospital, Acquaviva delle Fonti -Department of Medicine a, Bari, Italy; 6Unit of Immunology, Rheumatology, Allergy and Rare Diseases UnIRAR, Inflammation, Fibrosis and Ageing initiative INFL, Milano, Italy; 7Vita-Salute San Raffaele University, Milano, Italy; 8Department of Internal Medicine and Therapeutics, Università di Pavia, Italy; Division of Rheumatology, Fondazione IRCCS, Pavia, Italy; 9Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 10Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy; 11Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences and Community Health, Research Center for Adul, Milano, Italy; 12Department of Rheumatology, Sapienza University of Rome, Roma, Italy; 13Rheumatology Clinic Madonna dello Scoglio Crotonei, Crotone, Italy.
19 -
PO:01:003 | Sex-based differences in 2 years treatment outcomes with b/ts-DMARDs in psoriatic arthritis: from real-world evidence to predictive modeling from the Gruppo Italiano Studio Early Arthritis (GISEA) prospective registry Simone Perniola1, Florenzo Iannone1, Francesco Paolo Cantatore2, Angelo Semeraro3, Leonardo Santo4, Roberto Gorla5, Alberto Cauli6, Roberto Felice Caporali7, Bruno Frediani8, Rosario Foti9, Fabrizio Conti10, Marco Sebastiani11, Maria Sole Chimenti12, Roberta Ramonda13, Fabiola Atzeni14, Maurizio Rossini15, Serena Bugatti16, Serena Guiducci17, Giovanni Lapadula1, Gianfranco Ferraccioli18, Francesca Romana Spinelli10, Elisa Gremese19. | 1Rheumatology Unit, DiMePReJ, University of Bari, Bari; 2Rheumatology Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico Riuniti, Foggia; 3Rheumatology Unit, Martina Franca Hospital; 4Rheumatology Unit, ASL BT, P.O. Barletta; 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia; 6Rheumatology Unit, Department of Medical Science and Public Health, University of Cagliari, Monserrato (CA); 7Rheumatology Unit, Dipartimento di Reumatologia e Scienze Mediche, ASST PINI-CTO, University of Milano, Milano; 8Rheumatology Unit, Azienda Ospedaliero Universitaria Senese, Siena; 9Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania; 10Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and CV Sciences, Sapienza University of Rome, Roma; 11Rheumatology Unit, AUSL Piacenza, University of Parma, Parma; 12Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Roma; 13Rheumatology Unit, DIMED, University of Padua, Padova; 14Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina; 15Rheumatology Unit, Department of Medicine, University of Verona, Verona; 16Division of Rheumatology, Dept. of Internal Medicine and Therapy, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia; 17Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Firenze, Firenze; 18Department of Medicine, Catholic University of the Sacred Heart, Fondazione Policlinico Gemelli IRCCS, Roma; 19Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy
28 -
PO:02:016 | Real-world evidence of upadacitinib over two years in Italian patients with axial spondyloarthritis Mariagrazia Lorenzin1, Giacomo Cozzi1, Stefano Gentileschi2, Michele Maria Luchetti Gentiloni3, Antonio Carletto4, Maria Sole Chimenti5, Maria Manara6, Luca Quartuccio7, Rosario Foti8, Salvatore D'Angelo9, Ariela Hoxha10, Carlo Selmi11, Bernd Raffeiner12, Alessandro Giollo1, Alberto Cauli13, Carlo Salvarani14, Fabiola Atzeni15, Roberta Ramonda1, Sir Study Group Spa E Psa Antonio Spadaro16. | 1Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy; 2Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy; 3Clinica Medica, Ospedali Riuniti Ancona University Hospital, Ancona; Department of Clinical and Molecular Sciences, Ancona, Italy; 4Rheumatology Unit, Department of Medicine, AOUI University of Verona, Verona, Italy; 5Rheumatology, allergology and clinical Immunology, Department of Systems Medicine, University of Rome Tor Vergata, Roma, Italy; 6Humanitas San Pio X, Milano, Italy; 7University of Udine, Academic Hospital Santa Maria della Misericordia, Udine, Italy; 8Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania, Italy; 9Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy; 10Internal Medicine Unit, Thrombotic and Hemorrhagic Center, Department of Medicine-DIMED, University of Padua, Padova, Italy; 11Department of Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 12Department of Rheumatology, Teaching Hospital of the Paracelsius Medical Hospital of Bolzano ASAA-SABES, Bolzano, Italy; 13Rheumatology Unit, Department of Medical Sciences, AOU and University of Cagliari, Monserrato, Cagliari, Italy; 14Department of Rheumatology, Azienda USL-IRCCS di Reggio Emilia and Università di Modena and Reggio Emilia, Reggio Emilia, Italy; 15Rheumatology Unit, University of Messina, Messina, Italy; 16Società Italiana di Reumatologia, Milano, Italy.
26 -
PO:32:176 | Outcomes of upfront combination vs monotherapy with rituximab or mycophenolate mofetil for systemic sclerosis interstitial lung disease: results from a European Scleroderma Trials and Research cohort study Devis Benfaremo1, Corrado Campochiaro2, Gábor Kumánovics3, Christina Bergmann4, Elisabetta Zanatta5, David Launay6, Serena Guiducci7, Mickael Martin8, Carolina De Souza Müller9, Carlomaurizio Montecucco10, Luc Mouthon11, Gabriella Szucs12, Kastriot Kastrati13, Marie-Elise Truchetet14, Madelon Vonk15, Francesco Del Galdo16, Marco Matucci-Cerinic2, Gianluca Moroncini1, Yannick Allanore17. | 1Department of Clinical and Molecular Sciences, Marche Polytechnic University, Marche University Hospital, Ancona, Italy; 2Vita-Salute San Raffaele University, San Raffaele Hospital, Milano, Italy; 3University of Pécs, Department Of Rheumatology And Immunology, Pécs, Hungary; 4University Hospital Erlangen, Department Internal Medicine 3, Erlangen, Germany; 5Padova University Hospital, Rheumatology Unit, Padova, Italy; 6Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; 7University of Florence, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy; 8Poitiers University Hospital, Department of Internal Medicine Poitiers France; 9Hospital de Clinicas da Universidade Federal do Parana Curitiba Brazil; 10Università di Pavia e IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy; 11Hôpital Cochin, Department of Internal Medicine, Paris, France; 12University of Debrecen, Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary; 13Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; 14CHU de Bordeaux, Rheumatology department, Bordeaux, France; 15Radboudumc, Department of Rheumatology Nijmegen The Netherlands; 16Leeds Raynauds and Scleroderma Program, NIHR Biomedical Research Centre, Leeds, United Kingdom; 17Université Paris Cité, Cochin Hospital, Rheumatology Department, Paris, France.
13
